Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome
10.3969/j.issn.1001-5256.2021.10.038
- VernacularTitle:特利加压素联合白蛋白治疗肝肾综合征效果的预测因素
- Author:
Qianmei CAO
1
;
Zhechuan MEI
1
Author Information
1. Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
- Publication Type:Reviews
- Keywords:
Liver Cirrhosis;
Hepatorenal Syndrome;
Treatment Outcome
- From:
Journal of Clinical Hepatology
2021;37(10):2439-2443
- CountryChina
- Language:Chinese
-
Abstract:
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease often observed in advanced liver cirrhosis patients with circulatory dysfunction and tends to have poor prognosis. At present, terlipressin combined with albumin is the preferred drug treatment regimen for HRS. Many studies have been conducted on the predictive factors for the therapeutic effect of terlipressin combined with albumin, but there lacks a comprehensive report of these studies. This article reviews the latest research advances in this disease and its treatment from the pathogenesis of HRS and the mechanism of action of drugs, as well as the research advances in the predictive factors for the therapeutic effect of terlipressin combined with albumin in terms of baseline data, changes after treatment, and treatment regimens. It is pointed out that early identification of factors that can help predict treatment response has important clinical significance.
